FDA Approves Lilly Foundayo Oral GLP-1 Weight Loss Drug
INDIANAPOLIS, USA — April 1, 2026 In a landmark advancement in obesity treatment and metabolic disease management, Eli Lilly...
metabolic disease
Advertisement
Sun Pharma Launches Semaglutide in India Market
MUMBAI, INDIA, March 21, 2026 Sun Pharmaceutical Industries Limited has announced the launch of its semaglutide injection under the...
Innovent Doses First Patient in Phase 3 IBI128 Trial
San Francisco, USA / Suzhou, China | March 22, 2026 Innovent Biologics has announced that the first participant has...
Novo Nordisk Wegovy HD Approved with 20% Weight Loss
BAGSVÆRD, Denmark, March 19, 2026 Novo Nordisk A/S announced that the U.S. Food and Drug Administration (FDA) has approved...
Hanmi Expands GLP-1 Obesity Drug Reach Through Mexico Deal
SEOUL, SOUTH KOREA | January 27, 2026 — Hanmi Pharmaceutical, the core operating company of Hanmi Science, announced a...
Advertisements
Ascletis Expands ASC30 Oral GLP-1 Program for Obesity Treatment
Hong Kong, January 26, 2026 — Ascletis Pharma continued progress in the clinical development of ASC30, its investigational oral...
Junevity Study Reveals Single-Target Control of Cellular Aging
BOSTON, Massachusetts — January 12, 2026 — Junevity has announced the publication of its first peer-reviewed scientific study demonstrating...
Mazdutide 9mg Enters NMPA Review, Advancing Obesity Treatment
BEIJING, China, Nov. 25, 2025 — Innovent Biologics and Eli Lilly announced that the supplementary application for Mazdutide 9mg...
Pfizer Finalizes Metsera Acquisition to Expand Obesity Pipeline
NEW YORK, NY — November 14, 2025 — Pfizer announced it has completed its acquisition of Metsera, Inc., strengthening...
Lilly’s Oral GLP-1 Orforglipron Delivers Strong Phase 3 Results in Type 2 Diabetes
INDIANAPOLIS, Oct. 15, 2025 — Eli Lilly and Company (NYSE: LLY) announced positive topline results from two pivotal Phase...
Advertisement
